In scientific and laboratory environments, these compounds are often grouped together in studies involving connective tissue models, cellular repair pathways, and recovery-related mechanisms
Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial [Press release]
Sargsyan N, Chen JY, Aggarwal R, Fadel MG, Fehervari M, Ashrafian H (2024) The effects of bariatric surgery on cardiac function: a systematic review and meta-analysis
Br J Cancer 2012
Excessive Muscle Loss Signs Signs that lean mass loss may be occurring include rapidly declining strength, unusual fatigue during workouts, and muscle definition decrease despite scale weight continuing to drop
Recent Developments: 2025: Eli Lilly received FDA approval for tirzepatide (Zepbound) as a treatment for moderate-to-severe obstructive sleep apnea in adults with obesity the first pharmacotherapy approved for this indication expanding tirzepatide's approved uses beyond metabolic conditions into a respiratory indication affecting over 30 million Americans and supported by SURMOUNT-OSA trial data showing 63% reduction in apnea-hypopnea index
)
